MedPath

Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS

Not Applicable
Completed
Conditions
Signs and Symptoms, Digestive
HIV
Dietary Modification
Dyslipidemia
Interventions
Dietary Supplement: Maltodextrin (placebo for symbiotic)
Dietary Supplement: Symbiotic
Behavioral: Nutritional intervention
Registration Number
NCT02180035
Lead Sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Brief Summary

To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
290
Inclusion Criteria
  • HIV-infected patients
  • Adults (≥ 19 years old)
  • On highly active antiretroviral therapy (HAART)
Exclusion Criteria
  • Pregnancy
  • Breastfeeding
  • Opportunistic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Maltodextrin & Nutritional interventionNutritional interventionMaltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
Symbiotic & Nutritional interventionNutritional interventionSymbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
Maltodextrin & Nutritional interventionMaltodextrin (placebo for symbiotic)Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
Symbiotic & Nutritional interventionSymbioticSymbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
Primary Outcome Measures
NameTimeMethod
Seric lipid levelsBaseline, Week 24

Changes from baseline in total cholesterol, triglycerides, HDL-C and LDL-C.

Secondary Outcome Measures
NameTimeMethod
Gastrointestinal symptomsBaseline, Week 24

Assessment of the presence of gastrointestinal symptoms (nausea and/or vomiting, dyspepsia, heartburn, diarrhea, flatulence and constipation), associated or not with antiretrorival therapy, before and after intervention to verify their effectiveness in reducing these symptoms.

Body compositionBaseline, Week 24

Changes from baseline in total body fat percentage, percentage of fat in the trunk, percentage of fat in the arms, percentage of fat in the legs and lean body mass percentage.

Anthropometric measuresBaseline, Week 24

Changes from baseline in weight, waist circumference, abdominal circumference, waist-to-hip ratio and Body Mass Index (BMI).

Fasting blood glucoseBaseline, Week 24

Changes from baseline in fasting blood glucose.

Adherence to the nutritional intervention and nutritional appointmentsBaseline, Week 24

Assessment of dietary intake modification after intervention and patient's return to nutritional appointments.

Trial Locations

Locations (1)

Outpatient Infectoparasitary Diseases, Hospital das Clinicas, Federal University of Goiás

🇧🇷

Goiânia, Goiás, Brazil

© Copyright 2025. All Rights Reserved by MedPath